Comparative Pharmacology
Head-to-head clinical analysis: ARRANON versus TAZVERIK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARRANON versus TAZVERIK.
ARRANON vs TAZVERIK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Purine nucleoside analog; after intracellular phosphorylation to ara-GTP, it incorporates into DNA, inhibits DNA synthesis, and induces apoptosis in T-cell progenitors.
TAZVERIK is a histone methyltransferase EZH2 inhibitor. It selectively inhibits the enzymatic activity of EZH2, leading to decreased trimethylation of lysine 27 on histone H3 (H3K27me3), which results in reactivation of silenced genes and inhibition of proliferation in EZH2-mutant or wild-type cells.
2600 mg/m2 intravenously over 2 hours on days 1, 3, and 5, repeated every 28 days.
600 mg orally twice daily, with or without food, for advanced epithelioid sarcoma. Continue until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life of nelarabine is approximately 30 minutes; the active metabolite ara-G has a terminal half-life of approximately 20-24 hours. Clinically, this supports daily dosing in cycles.
Terminal elimination half-life is approximately 3.6 hours (range 1.6–7.1 hours) in patients with epithelioid sarcoma at steady state. Short half-life supports twice-daily dosing. Consider accumulation with renal or hepatic impairment.
Nelarabine is extensively metabolized to ara-G; elimination is primarily renal: ~27% as parent drug and 30-50% as ara-G in urine. Fecal excretion accounts for <5% of administered dose.
Primarily hepatobiliary excretion: approximately 70% of the dose recovered in feces as unchanged drug and metabolites, with <1% excreted renally as unchanged tazemetostat.
Category C
Category C
Antineoplastic
Antineoplastic, EZH2 Inhibitor